Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gaviscon Advance instructions during pre-investigation PPI washout
2019-004561-41Phase 4Unknown
- Sponsor
- The Functional Gut Clinic
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of gaviscon advance in gastroesophageal reflux disease (GERD) (2 arms), sponsored by The Functional Gut Clinic. Primary endpoint: Mean change in GERD-HRQL score. Status: unknown.
02
Drugs
gaviscon advance
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2019-004561-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004561-41.